$RAPT
RAPT Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022024191 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $966.0K
YoY Change -100.0% -100.0% -36.78%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.977M $5.079M $3.774M
YoY Change 10.82% 34.58% 17.94%
% of Gross Profit
Research & Development $19.45M $16.60M $15.73M
YoY Change 36.05% 5.56% 21.8%
% of Gross Profit
Depreciation & Amortization $252.0K $260.0K $229.0K
YoY Change 9.09% 13.54% -11.92%
% of Gross Profit
Operating Expenses $24.43M $21.68M $19.50M
YoY Change 30.02% 11.17% 21.04%
Operating Profit -$21.68M -$18.53M
YoY Change 16.97%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.480M $443.0K -$118.0K
YoY Change 1309.52% -475.42% -149.17%
Pretax Income -$22.95M -$21.24M -$18.65M
YoY Change 28.01% 13.85% 30.03%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$22.95M -$21.24M -$18.65M
YoY Change 28.01% 13.85% 27.48%
Net Earnings / Revenue -1930.75%
Basic Earnings Per Share -$0.63 -$0.63
Diluted Earnings Per Share -$0.64 -$0.63 -$632.4K
COMMON SHARES
Basic Shares Outstanding 29.91M 29.66M 29.49M
Diluted Shares Outstanding 33.68M 29.49M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $249.1M $195.4M $210.8M
YoY Change 31.33% -7.28% 71.65%
Cash & Equivalents $38.95M $27.71M $60.00M
Short-Term Investments $210.1M $167.7M $150.8M
Other Short-Term Assets $3.626M $2.458M $3.709M
YoY Change 9.25% -33.73% 37.37%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $252.7M $197.9M $214.5M
YoY Change 30.95% -7.74% 70.91%
LONG-TERM ASSETS
Property, Plant & Equipment $2.539M $2.742M $2.578M
YoY Change -7.37% 6.36% -16.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.036M $3.071M $389.0K
YoY Change 38.12% 689.46% -2.75%
Total Long-Term Assets $13.52M $11.60M $2.967M
YoY Change 138.65% 290.8% -15.23%
TOTAL ASSETS
Total Short-Term Assets $252.7M $197.9M $214.5M
Total Long-Term Assets $13.52M $11.60M $2.967M
Total Assets $266.2M $209.5M $217.5M
YoY Change 34.02% -3.67% 68.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.365M $4.043M $4.017M
YoY Change 68.33% 0.65% -8.7%
Accrued Expenses $8.656M $8.240M $6.845M
YoY Change 36.83% 20.38% 20.09%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.22M $13.87M $12.70M
YoY Change 48.24% 9.23% -18.57%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.819M $6.316M $2.894M
YoY Change 156.26% 118.24% -12.3%
Total Long-Term Liabilities $6.819M $6.316M $2.894M
YoY Change 156.26% 118.24% -12.3%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.22M $13.87M $12.70M
Total Long-Term Liabilities $6.819M $6.316M $2.894M
Total Liabilities $21.04M $20.18M $15.59M
YoY Change 71.7% 29.47% -17.52%
SHAREHOLDERS EQUITY
Retained Earnings -$367.9M -$344.9M
YoY Change 29.52%
Common Stock $613.1M $534.7M
YoY Change 30.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $245.2M $189.3M $201.9M
YoY Change
Total Liabilities & Shareholders Equity $266.2M $209.5M $217.5M
YoY Change 34.02% -3.67% 68.58%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$22.95M -$21.24M -$18.65M
YoY Change 28.01% 13.85% 27.48%
Depreciation, Depletion And Amortization $252.0K $260.0K $229.0K
YoY Change 9.09% 13.54% -11.92%
Cash From Operating Activities -$22.85M -$17.15M -$12.52M
YoY Change 10.48% 36.98% 25.69%
INVESTING ACTIVITIES
Capital Expenditures $49.00K -$81.00K -$70.00K
YoY Change -112.44% 15.71% -41.67%
Acquisitions
YoY Change
Other Investing Activities -$41.22M -$17.52M -$14.10M
YoY Change 165.98% 24.21% -1295.25%
Cash From Investing Activities -$41.27M -$17.60M -$14.17M
YoY Change 159.69% 24.16% -1437.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 75.36M 5.251M 472.0K
YoY Change 12438.94% 1012.5% 195.0%
NET CHANGE
Cash From Operating Activities -22.85M -17.15M -12.52M
Cash From Investing Activities -41.27M -17.60M -14.17M
Cash From Financing Activities 75.36M 5.251M 472.0K
Net Change In Cash 11.24M -29.50M -26.22M
YoY Change -131.25% 12.49% 200.01%
FREE CASH FLOW
Cash From Operating Activities -$22.85M -$17.15M -$12.52M
Capital Expenditures $49.00K -$81.00K -$70.00K
Free Cash Flow -$22.90M -$17.07M -$12.45M
YoY Change 12.87% 37.1% 26.51%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
rapt Issuance Costs Related To Public Offering Included In Accrued Expenses
IssuanceCostsRelatedToPublicOfferingIncludedInAccruedExpenses
dei Amendment Flag
AmendmentFlag
false
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001673772
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38997
dei Entity Registrant Name
EntityRegistrantName
RAPT Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3313701
dei Entity Address Address Line1
EntityAddressAddressLine1
561 Eccles Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
489-9000
dei Security12b Title
Security12bTitle
Common Stock $0.0001 par value per share
dei Trading Symbol
TradingSymbol
RAPT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29910852
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27706000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24027000
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
167730000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
165627000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2458000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3319000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
197894000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
192973000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2742000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2741000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5782000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3071000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2922000
CY2022Q3 us-gaap Assets
Assets
209489000
CY2021Q4 us-gaap Assets
Assets
198636000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4043000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1999000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8240000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6326000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1016000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1551000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
33000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
254000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
13867000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9595000
CY2021Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2150000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
511000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6316000
CY2022Q3 us-gaap Liabilities
Liabilities
20183000
CY2021Q4 us-gaap Liabilities
Liabilities
12256000
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
534689000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
470629000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-453000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-206000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-344933000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-284046000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
189306000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
186380000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
209489000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
198636000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
966000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1527000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3057000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16599000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15725000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47628000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42686000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5079000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3774000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15263000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11546000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
21678000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
19499000
us-gaap Operating Expenses
OperatingExpenses
62891000
us-gaap Operating Expenses
OperatingExpenses
54232000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21678000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18533000
us-gaap Operating Income Loss
OperatingIncomeLoss
-61364000
us-gaap Operating Income Loss
OperatingIncomeLoss
-51175000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
443000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-118000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
477000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-100000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-21235000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-18651000
us-gaap Net Income Loss
NetIncomeLoss
-60887000
us-gaap Net Income Loss
NetIncomeLoss
-51275000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
366000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
173000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
715000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
281000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-74000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-962000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-59000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20943000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18469000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-61134000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-51053000
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.63
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.63
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.63
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.63
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.93
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.93
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.92
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.92
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33684261
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33684261
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29491857
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29491857
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31481948
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31481948
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26663209
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26663209
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
186380000
CY2022Q1 rapt Stock Issued During Period Value Employee Stock Plans
StockIssuedDuringPeriodValueEmployeeStockPlans
132000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2702000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-201000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-710000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-20468000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
167835000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
49784000
CY2022Q2 rapt Stock Issued During Period Value Employee Stock Plans
StockIssuedDuringPeriodValueEmployeeStockPlans
654000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2672000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
550000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-178000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-19184000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
202133000
CY2022Q3 rapt Stock Issued During Period Value Employee Stock Plans
StockIssuedDuringPeriodValueEmployeeStockPlans
272000
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2865000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
366000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-74000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-21235000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
189306000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
104179000
CY2021Q1 rapt Stock Issued During Period Value Employee Stock Plans
StockIssuedDuringPeriodValueEmployeeStockPlans
121000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2687000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
38000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-50000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16514000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
91641000
CY2021Q2 rapt Stock Issued During Period Value Employee Stock Plans
StockIssuedDuringPeriodValueEmployeeStockPlans
1016000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2888000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
70000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-18000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-16110000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
217579000
CY2021Q3 rapt Stock Issued During Period Value Employee Stock Plans
StockIssuedDuringPeriodValueEmployeeStockPlans
472000
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2291000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
173000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-18651000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
201873000
us-gaap Profit Loss
ProfitLoss
-60887000
us-gaap Profit Loss
ProfitLoss
-51275000
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
359000
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
840000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
795000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
765000
us-gaap Share Based Compensation
ShareBasedCompensation
8239000
us-gaap Share Based Compensation
ShareBasedCompensation
7866000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-715000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-281000
rapt Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
1282000
rapt Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-712000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-379000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3973000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3551000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1527000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2676000
rapt Increase Decrease In Deferred Rent Current And Noncurrent
IncreaseDecreaseInDeferredRentCurrentAndNoncurrent
0
rapt Increase Decrease In Deferred Rent Current And Noncurrent
IncreaseDecreaseInDeferredRentCurrentAndNoncurrent
-76000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1583000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47922000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40345000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
112718000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
148050000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
109294000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
82956000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
796000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
361000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4220000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-65455000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
49784000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
134582000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1058000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1609000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55821000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
140881000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3679000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
35081000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24027000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24918000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27706000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
59999000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
6585000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
rapt Issuance Costs Related To Public Offering Included In Accrued Expenses
IssuanceCostsRelatedToPublicOfferingIncludedInAccruedExpenses
370000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10425000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8007000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7684000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2742000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2741000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Organization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Description of the Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RAPT Therapeutics, Inc. (“RAPT” or the “Company”) is a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary drug discovery and development engine, the Company develops highly selective small molecules that are designed to modulate the critical immune responses underlying these diseases.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is located in South San Francisco, California.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
195494000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1202000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
194297000
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
26567000
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
26567000
CY2022Q3 rapt Marketable Securities At Amortized Cost
MarketableSecuritiesAtAmortizedCost
168927000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
800000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
800000
CY2022Q3 rapt Marketable Securities At Unrealized Gains
MarketableSecuritiesAtUnrealizedGains
5000
CY2022Q3 rapt Marketable Securities At Unrealized Losses
MarketableSecuritiesAtUnrealizedLosses
1202000
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
167730000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
188520000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
235000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
188285000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
22658000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
22658000
CY2021Q4 rapt Marketable Securities At Amortized Cost
MarketableSecuritiesAtAmortizedCost
165862000
CY2021Q4 rapt Marketable Securities At Unrealized Losses
MarketableSecuritiesAtUnrealizedLosses
235000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
165627000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
167730000
CY2022Q3 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
167730000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10749000
CY2022Q3 rapt Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
3859000
CY2021Q4 rapt Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2205000
CY2022Q3 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
3943000
CY2021Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
3652000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
265000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
415000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
173000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
54000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8240000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6326000
CY2015Q2 rapt Operating Lease Expiration Year
OperatingLeaseExpirationYear
2022-05
CY2018Q2 rapt Additional Square Feet Area Of Laboratory And Office Facilities Under Lease
AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease
6378
CY2018Q2 rapt Increased Area Of Leased Premises
IncreasedAreaOfLeasedPremises
36754
CY2018Q2 rapt Lessee Operating Lease Extended Lease Term
LesseeOperatingLeaseExtendedLeaseTerm
2026-11
CY2015Q2 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2015Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
23300000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-21235000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-18651000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
514000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2109000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2183000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2259000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2137000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
9202000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1335000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
7867000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5782000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1551000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6316000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
7867000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1300000
CY2022Q3 us-gaap Lease Cost
LeaseCost
600000
us-gaap Lease Cost
LeaseCost
1500000
us-gaap Operating Lease Payments
OperatingLeasePayments
1600000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y2M1D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
us-gaap Net Income Loss
NetIncomeLoss
-60887000
us-gaap Net Income Loss
NetIncomeLoss
-51275000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33684261
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33684261
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29491857
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29491857
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31481948
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31481948
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26663209
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10368861
CY2022Q2 rapt Beneficial Ownership Limitation Percentage Of Shares Outstanding Minimum
BeneficialOwnershipLimitationPercentageOfSharesOutstandingMinimum
0.0999
CY2022Q2 rapt Beneficial Ownership Limitation Percentage Of Shares Outstanding Maximum
BeneficialOwnershipLimitationPercentageOfSharesOutstandingMaximum
0.1999
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26663209
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2865000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2005000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8239000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7866000
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.93
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.92
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.92
CY2022Q3 rapt Pre Funded Warrants To Purchase Common Stock
PreFundedWarrantsToPurchaseCommonStock
4000000
rapt Pre Funded Warrants To Purchase Common Stock
PreFundedWarrantsToPurchaseCommonStock
4000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3016697
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2046367

Files In Submission

Name View Source Status
0000950170-22-024191-index-headers.html Edgar Link pending
0000950170-22-024191-index.html Edgar Link pending
0000950170-22-024191.txt Edgar Link pending
0000950170-22-024191-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rapt-20220930.htm Edgar Link pending
rapt-20220930.xsd Edgar Link pending
rapt-ex10_1.htm Edgar Link pending
rapt-ex31_1.htm Edgar Link pending
rapt-ex31_2.htm Edgar Link pending
rapt-ex32_1.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
rapt-20220930_cal.xml Edgar Link unprocessable
rapt-20220930_def.xml Edgar Link unprocessable
rapt-20220930_pre.xml Edgar Link unprocessable
rapt-20220930_lab.xml Edgar Link unprocessable
rapt-20220930_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable